Jul 28, 2022
Immutep Quarterly Activities Report
Jul 05, 2022
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
Jun 26, 2022
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
Jun 03, 2022
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers
Jun 01, 2022
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
